ArticlePLoS pathogens2016
Insufficient Evidence for Rare Activation of Latent HIV in the Absence of Reservoir-Reducing Interventions.
Abstract readComment
In one paragraph
Article in PLoS pathogens, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Clinical trial simulation of antiviral drugs.Journal of virology · 2026Review
- Clonally expanded HIV-1 proviruses with 5'-leader defects can give rise to nonsuppressible residual viremia.The Journal of clinical investigation · 2023Article
- Dynamics of latent HIV under clonal expansion.PLoS pathogens · 2021Article
- Unified model of short- and long-term HIV viral rebound for clinical trial planning.Journal of the Royal Society, Interface · 2021Article
- Models of SIV rebound after treatment interruption that involve multiple reactivation events.PLoS computational biology · 2020Article
- The Glutamate System as a Crucial Regulator of CNS Toxicity and Survival of HIV Reservoirs.Frontiers in cellular and infection microbiology · 2020Review
- Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers.PLoS computational biology · 2019Article
- Phylogenetic approach to recover integration dates of latent HIV sequences within-host.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Modeling HIV persistence and cure studies.Current opinion in HIV and AIDS · 2018Review
- Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir.BMC biology · 2018Article
- Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency.Journal of virology · 2018Article
- Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy.PLoS pathogens · 2017Article
- Modeling Kick-Kill Strategies toward HIV Cure.Frontiers in immunology · 2017Review
- Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 Days.PLoS pathogens · 2016Article
- Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV.PLoS pathogens · 2016Article
- Mathematical Models of HIV Latency.Current topics in microbiology and immunologyReview
Corrections and comments
- Commented on by
- Comment on
Authors and funding
4 authors.
Alison L HillProgram for Evolutionary Dynamics, Department of Mathematics, Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts, United States of America.ORCID 0000-0002-6583-3623
Daniel I S RosenbloomDepartment of Biomedical Informatics, Columbia University Medical Center, New York, New York, United States of America.
Janet D SilicianoDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Robert F SilicianoDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Funding
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4MVaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0MUsing NK Cells to eliminate the latent HIV reservoirU19AI096113 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LUCIW, PAUL · 2011 to 2015
$39.5MViral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SCHACKER, TIMOTHY W · 2011 to 2015
$29.5MTraining in Biomedical Informatics at Columbia UniversityT15LM007079 · NLM · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI NOEMIE ELHADAD, GEORGE M HRIPCSAK · 1992 to 2026
$28.9MLATENT VIRAL RESERVOIRS IN HIV1 INFECTIONR01AI043222 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SILICIANO, ROBERT F · 1998 to 2013
$3.5MQuantification and prediction of treatment efficacy for HIV cure strategiesDP5OD019851 · OD · JOHNS HOPKINS UNIVERSITY · PI HILL, ALISON LYNN · 2014 to 2018
$2.1MUncovering Evolutionary History using the Topology of Genomic Data with Applications to HIVR01GM117591 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI RABADAN, RAUL · 2015 to 2018
$1.3MNIAID NIH HHS P30 AI060354NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI043222NIAID NIH HHS U19 AI096109NIAID NIH HHS U19 AI096113NIGMS NIH HHS R01 GM117591NIH AI096113NIH P30AI060354NIH P30AI094189NIH R01AI043222NIH R01GM117591NIH T15LM007079NIH U19AI096109NIH HHS DP5 OD019851NLM NIH HHS T15 LM007079
Abstract
PubMed holds no abstract for this paper.
Indexed as
HIV-1Virus LatencyDrug ResistanceGenetic Variation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.